Lee Chuhee
Department of Biochemistry and Molecular Biology, School of Medicine, Yeungnam University, Daegu 705‑717, Republic of Korea.
Mol Med Rep. 2015 Jul;12(1):1485-92. doi: 10.3892/mmr.2015.3542. Epub 2015 Mar 24.
The majority of patients with ovarian cancer are diagnosed at the advanced stages (III/IV) and their 5-year-survival rate is relatively low. One of the major causes of the poor prognosis of ovarian cancer is the development of resistance to first-line chemotherapy, including platinum and taxol. Therefore, improvements in current understanding of chemoresistance is required for the successful treatment of ovarian cancer. In the present study, taxol-resistant ovarian cancer cells, SKOV3/TR, were established by exposing parental SKOV3 cells to increasing concentrations of taxol. . Briefly, cells were treated with 1.5 nM (for 4 weeks), 3 nM (for 4 weeks), 6 nM (for 5 weeks), 12 nM (for 5 weeks) and 24 nM taxol (for 8 weeks) over 6 months. The SKOV3/TR cells were found to be smaller in size and rounder in shape compared with their parental cells. Cell viability and colony formation assays demonstrated an increase in the population doubling time of the SKOV3/TR cells, indicating a reduction in the proliferative capacity of these cells. Reverse transcription-polymerase chain reaction and western blot analysis revealed that, among the TAM receptor tyrosine kinases (RTKs), the mRNA and protein expression levels of Tyro3 RTK were increased, while those of Axl and Mer RTK were decreased in the SKOV3/TR cells. In addition, restoration of the level of Tyro3 by transfecting Tyro3-specific small interfering RNA into the SKOV3/TR cells reduced the proliferative capacity of the cells, indicating that upregulation of the expression of Tyro3 in SKOV3/TR cells may promote survival in the presence of taxol, which eventually resulted in the acquisition of resistance upon taxol treatment. The present study subsequently found that, in the SKOV3/TR cells, the level of intracellular reactive oxygen species (ROS) was elevated, and antioxidant treatment with N-acetyl cysteine (NAC) exerted more profound antiproliferative effects compared with the parental cells. The western blot analysis demonstrated that treatment of the SKOV3/TR cells with NAC reduced the protein expression of Tyro3, and the inhibitory effect of NAC on the phosphorylation of Akt was increased, which may have had a positive effect on the proliferation of the SKOV3/TR cells. The levels of phosphorylation and protein expression of signal transducers and activators of transcription 3 (STAT3) were not affected by NAC treatment, indicating that the phosphorylation of Akt, but not expression or phosphorylation of STAT3, was associated with the increased intracellular ROS level in the SKOV3/TR cells. Taken together, the results of the present study demonstrated that the acquired taxol resistance of ovarian cancer cells was associated with ROS-dependent upregulation in the expression of Tyro3 RTK and the subsequent activation of Akt.
大多数卵巢癌患者在晚期(III/IV期)被诊断出来,其5年生存率相对较低。卵巢癌预后不良的主要原因之一是对一线化疗(包括铂类和紫杉醇)产生耐药性。因此,要成功治疗卵巢癌,需要加深对化疗耐药性的现有认识。在本研究中,通过将亲本SKOV3细胞暴露于浓度不断增加的紫杉醇中,建立了耐紫杉醇的卵巢癌细胞SKOV3/TR。简而言之,在6个月的时间里,细胞分别用1.5 nM(处理4周)、3 nM(处理4周)、6 nM(处理5周)、12 nM(处理5周)和24 nM紫杉醇(处理8周)进行处理。结果发现,与亲本细胞相比,SKOV3/TR细胞体积更小,形状更圆。细胞活力和集落形成试验表明,SKOV3/TR细胞的群体倍增时间增加,表明这些细胞的增殖能力降低。逆转录-聚合酶链反应和蛋白质印迹分析显示,在酪氨酸激酶家族(TAM)受体酪氨酸激酶(RTK)中,SKOV3/TR细胞中Tyro3 RTK的mRNA和蛋白质表达水平升高,而Axl和Mer RTK的表达水平降低。此外,通过将Tyro3特异性小干扰RNA转染到SKOV3/TR细胞中恢复Tyro3水平,降低了细胞的增殖能力,这表明SKOV3/TR细胞中Tyro3表达的上调可能在紫杉醇存在的情况下促进细胞存活,最终导致在紫杉醇处理后获得耐药性。本研究随后发现,在SKOV3/TR细胞中,细胞内活性氧(ROS)水平升高,与亲本细胞相比,用N-乙酰半胱氨酸(NAC)进行抗氧化处理具有更显著的抗增殖作用。蛋白质印迹分析表明,用NAC处理SKOV3/TR细胞可降低Tyro3的蛋白质表达,并且NAC对Akt磷酸化的抑制作用增强,这可能对SKOV3/TR细胞的增殖产生了积极影响。NAC处理不影响信号转导和转录激活因子3(STAT3)的磷酸化水平和蛋白质表达,这表明Akt的磷酸化而非STAT3的表达或磷酸化与SKOV3/TR细胞中细胞内ROS水平升高有关。综上所述,本研究结果表明,卵巢癌细胞获得性紫杉醇耐药与ROS依赖的Tyro3 RTK表达上调及随后的Akt激活有关。